Neuropsychiatric systemic lupus erythematosus

Current Neuropharmacology

Volumn 9, Issue 3, 2011, Pages 449-457

  Popescu, Alexandra ^a   Kao, Amy H ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b ALLEGHENY HEALTH NETWORK   (United States)

Author keywords

Autoantibody; Autoimmunity; Immunosuppression; Neuropsychiatric lupus; SLE

Indexed keywords

ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; AZATHIOPRINE; BELIMUMAB; CYCLOPHOSPHAMIDE; FLUORODEOXYGLUCOSE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IBUPROFEN; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RITUXIMAB; STEROID;

ABORTION; ANXIETY DISORDER; ARTICLE; ASEPTIC MENINGITIS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; CONFUSION; CORTICOSTEROID THERAPY; CRANIAL NEUROPATHY; DEMYELINATING DISEASE; DIABETES MELLITUS; DRUG MEGADOSE; DYSLIPIDEMIA; FATIGUE; FEVER; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GASTROINTESTINAL HEMORRHAGE; GUILLAIN BARRE SYNDROME; HEADACHE; HEMOLYSIS; HUMAN; HYPERTENSION; INFECTION; KIDNEY DISEASE; LOW DRUG DOSE; MENTAL DISEASE; MONONEUROPATHY; MOOD DISORDER; MOTOR DYSFUNCTION; MUSCULOSKELETAL DISEASE; MYASTHENIA GRAVIS; NERVE INJURY; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROPSYCHIATRIC SYSTEMATIC LUPUS ERYTHEMATOSUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMAPHERESIS; POLYNEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PSYCHOSIS; RETINOPATHY; SEIZURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINAL CORD DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TOXIC MYOPATHY; TREATMENT DURATION;

EID: 79960973850     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015911796557984     Document Type: Article

References (119)

1. Danchenko, N.; Satia J.; Anthony, M. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus, 2006, 15(5), 308-318.
2. Rönnblom, L.; Alm, G. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J. Exp. Med., 2001, 194(12), F59-F63.
3. Rönnblom, L.; Pascual, V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus, 2008, 17, 394-399.
4. Crow, M. Interferon-alpha: a therapeutic target in systemic lupus erythematosus. Rheum. Dis. Clin. North Am., 2010, 36(1), 173-186.
5. Bengtsson, A.A.; Sturfelt, G.; Truedsson, L.; Blomberg, J.; Alm, G.; Vallin, H.; Rönnblom, L. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus, 2000, 9(9), 664-671.
6. Kirou, K.A.; Lee, C.; George, S.; Louca, K.; Peterson, M.G.E.; Crow, M.K. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum., 2005, 52(5), 1491-503.
7. Ainiala, H.; Loukkola, J.; Peltola, J.; Korpela, M.; Hietaharju, A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology, 2001, 57, 496-499.
8. Brey, R.; Holliday, S.L.; Saklad, A.R. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology, 2002, 58(8), 1214-1220.
9. Hanly, J.G.; Urowitz, M.B.; Sanchez-Guerrero, J.; Bae, S.C.; Gordon, C.; Wallace, D.J.; Isenberg, D.; Alarcón, G.S.; Clarke, A.; Bernatsky, S.; Merrill, J.T.; Petri, M.; Dooley, M.A.; Gladman, D.; Fortin, P.R.; Steinsson K.; Bruce I.; Manzi S.; Khamashta M.; Zoma A.; Aranow C.; Ginzler E.; Vollenhoven R.V.; Font J.; Sturfelt G.; Nived O.; Ramsey-Goldman R.; Kalunian K.; Douglas J.; Thompson K.; Farewell V. Systemic Lupus International Collaborating Clinics. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study. Arthritis Rheum., 2007, 56(1), 265-273.
10. Zhu, T.Y.; Tam, L.S.; Lee, V.W.; Lee, K.K.; Li, E.K. Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: a cost-of-illness study in Hong Kong. Rheumatology (Oxford), 2009, 48(5), 564-568.
11. Muscal, E.; Brey, R.L. Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol. Clin., 2010, 28(1), 61-73.
12. Mikdashi, J.; Handwerger, B. Predictors of neuropsychiatric damage in systemic lupus erythematosus. Rheumatology, 2004, 43, 1555-1560.
13. Harel, L.; Sandborg, C.; Lee, T.; von Scheven, E. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J. Rheumatol., 2006, 33(9), 1873-1877.
14. Sibbitt, W.L Jr.; Brandt, J.R.; Johnson, C.R.; Maldonado, M.E.; Patel, S.R.; Ford, C.C.; Bankhurst, A.D.; Brooks, W.M. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J. Rheumatol., 2002, 29(7), 1536-1542.
15. Benseler, S.; Silverman, E. Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus, 2007, 16, 564-571.
16. Hiraki, L.T.; Benseler, S.M.; Tyrrell, P.N.; Hebert, D.; Harvey, E.; Silverman, E.D. Clinical and laboratory characteristics and long- term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J. Pediatr., 2008, 152(4), 550-556.
17. Sabbadini, M.; Manfredi, A.; Bozzolo, E.; Ferrario, L.; Rugarli, C.; Scorza, R.; Origgi, L.; Vanoli, M.; Gambini, O.; Vanzulli, L.; Croce, D.; Campana, A.; Messa, C.; Fazio, F.; Tincani, A.; Anzola, G.; Cattaneo, R.; Padovani, A.; Gasparotti, R.; Gerli, R.; Quartesan, R.; Piccirilli, M.; Farsi, A.; Emmi, E.; Passaleva, A. Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus, 1999, 8(1), 11-19.
18. Hanly, J.; Fisk, J.; McCurdy G.; Fougere L.; Douglas J. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. J. Rheumatol., 2005, 32(8), 1459-1456.
19. Kovacs, J.; Urowitz, M.; Gladman, D. Dilemmas in neuro- psychiatric lupus. Rheum. Dis. Clin. North Am., 1993, 19, 795-819.
20. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum., 1999, 42, 599-608.
21. Hanly, J.G.; Hong, C.; Smith, S.; Fisk, J.D. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum., 1999, 42(4), 728-734.
22. Carbotte, R.M.; Denburg, S.D.; Denburg, J.A. Prevalence of cognitive impairment in systemic lupus erythematosus. J. Nerv. Ment. Dis., 1986, 174, 357-364.
23. Denburg, S.D.; Carbotte, R.M.; Denburg, J.A. Cognitive impairment in systemic lupus erythematosus: a neuropsychological study of individual and group deficits. J. Clin. Exp. Neuropsychol., 1987, 9, 323-339.
24. Hanly, J.; Robichaud, J.; Fisk, J. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J. Rheumatol., 2006, 33(8), 1553-1558.
25. Olazarán J.; López-Longo J.; Cruz I.; Bittini A.; Carreño L. Cognitive Dysfunction in Systemic Lupus Erythematosus. Prevalence Correlates Eur. Neurol., 2009, 62(1), 49-55.
26. Tan, E.; Cohen, A.; Fries, J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum., 1982, 25, 1271-1277.
27. Hochberg, M. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum., 1997, 40(9), 1725.
28. De Marcaida, J.A.; Reik, L. Jr. Disorders that mimic central nervous system infections. Neurol. Clin., 1999, 17(4), 901-941.
29. Belmont, H.M.; Abramson S.B.; Lie J.T. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Arthritis Rheum., 1996, 39(1), 9-22.
30. Hanly, J.G.; Walsh, N.M.; Sangalang, V. Brain pathology in systemic lupus erythematosus. J. Rheumatol., 1992, 19, 732-741.
31. Abbott, N.J.; Mendonca, L.L.; Dolman, D.E. The blood-brain barrier in systemic lupus erythematosus. Lupus, 2003, 12, 908-915.
32. Spronk, P.E. Bootsma, H.; Huitema, M.G.; Limburg, P.C.; Kallenberg, C.G. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin. Exp. Immunol., 1994, 97(3), 439-444.
33. Nishimura, K.; Harigai, M.; Omori, M.; Sato, E.; Hara, M. Blood- brain barrier damage as a risk factor for corticosteroid-induced psychiatric disorders in systemic lupus erythematosus. Psychoneuroendocrinology, 2008, 33(3), 395-403.
34. Kowal, C.; DeGiorgio, L.A.; Lee, J.Y.; Edgar, M.A.; Huerta, P.T.; Volpe, B.T.; Diamond, B. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc. Natl. Acad. Sci. USA, 2006, 103(52), 19854-19859.
35. Huerta, P.T.; Kowal, C.; DeGiorgio, L.A.; Volpe, B.T.; Diamond, B. Immunity and behavior: Antibodies alter emotion. Proc. Natl. Acad. Sci. U. S. A., 2006, 103(3), 678-683.
36. Kowal, C.; DeGiorgio, L.A.; Nakaoka, T.; Hetherington, H.; Huerta, P.T.; Diamond, B.; Volpe, B.T. Cognition and immunity; antibody impairs memory. Immunity, 2004, 2004(21), 2.
37. DeGiorgio, L.A.; Konstantinov, K.N.; Lee, S.C.; Hardin, J.A.; Volpe, B.T.; Diamond, B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat.Med., 2001, 7(11), 1189-1193.
38. Ernerudh, J. Oisson, T.; Lindström, F.; Skogh, T. Cerebrospinal fluid immunoglobulin abnormalities in systemic lupus erythematosus. J. Neurol. Neurosurg. Psychiatry, 1985, 48(8), 807-813.
39. Hirohata, S.; Hirose, S.; Miyamoto, T. Cerebrospinal fluid IgM, IgA, and IgG indexes in systemic lupus erythematosus: their use as estimates of central nervous system disease activity. Arch. Intern. Med., 1985, 145(10), 1843-1846.
40. Brandão, C.O.; Ruocco, H.H.; Farias A. S.; Oliveira, C.; Hallal- Longo, D.E.; Mirandola, S.R.; Oliveira, E.C.; Cendes, F.; Damasceno, B.P.; Santos, L.M. Cytokines and intrathecal IgG synthesis in multiple sclerosis patients during clinical remission. Arq. Neuropsiquiatr., 2005, 63(4), 914-919.
41. Danowski, A.; de Azevedo, M.N.; de Souza P.J.A.; Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J. Rheumatol., 2009, 36(6), 1195-1199.
42. Escalante, A.; Brey, R.; Mitchell, B.; Dreiner, U. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am. J. Med., 1995, 98, 559-567.
43. Levine, J.; Branch, D.; Rauch, J. The antiphospholipid syndrome. N. Engl. J. Med., 2002, 346, 752-763.
44. Merkel, P.A.; Chang, Y.; Pierangeli, S.S.; Convery, K.; Harris, E.N.; Polisson, R.P. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am. J. Med., 1996, 101, 576-583.
45. Cervera, R.; Khamashta, M.A.; Font, J.; Sebastiani, G.D.; Gil, A.; Lavilla, P.; Domenech, I.; Aydintug, O.; Jedryka-Goral, A.; De Ramon, E.; Galeazzi, M.; Haga, H.J.; Mathieu, A.; Houssiau, F.; Ingelmo, M.; Hughes, G.R. The European Working Party on Systemic Lupus Erythematosus. Systemic lupus erythematosus- clinical and immunologic patterns of disease expression in a cohort of 1, 000 patients. The european working party on systemic lupus erythematosus. Medicine, 1993, 72, 113-124.
46. Greenwood, D.L.; Gitlits, V.M.; Alderuccio, F.; Sentry, J.W.; Toh, B.H. Autoantibodies in neuropsychiatric lupus. Autoimmunity, 2002, 35(2), 79-86.
47. Kent, M.; Alvarez, F.; Vogt, E.; Fyffe, R.; Ng, A.; Rote, N. Monoclonal antiphosphatidylserine antibodies react directly with feline and murine central nervous system. J. Rheumatol., 1997, 24(9), 1725-1733.
48. Shoenfeld, Y.; Nahum, A.; Korczyn, A.; Dano, M.; Rabinowitz, R.; Beilin, O.; Pick, C.; Leider-Trejo, L.; Kalashnikova, L.; Blank, M.; Chapman, J. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus, 2003, 12(6), 436-442.
49. Caronti, B.; Calderaro, C.; Alessandri, C.; Conti, F.; Tinghino, R.; Pini, C.; Palladini, G.; Valesini, G. Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J. Autoimmun., 1998, 11(5), 425-429.
50. Caronti, B.; Pittoni, V.; Palladini, G.; Valesini, G. Anti-beta 2- glycoprotein I antibodies bind to central nervous system. J. Neuro Sci., 1998, 156(2), 211-219.
51. Cervera, R.; Khamashta, M.A.; Font, J.; Sebastiani, G.D.; Gil, A.; Lavilla, P.; Mejia, J.C.; Aydintug, A.O.; Chwalinska-Sadowska, H.; de Ramon, E.; Fernandez-Nebro, A.; Galeazzi, M.; Valen, M.; Mathieu, A.; Houssiau, F.; Caro, N; Alba, P.; Ramos-Casals, M.; Ingelmo, M.; Hughes, G.R.V. European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1, 000 patients. Medicine, 2003, 82(5), 299-308.
52. Menon, S.; Jameson-Shortall, E.; Newman, S.P.; Hall-Craggs, M.R.; Chinn, R.; Isenberg, D.A. A longitudinal study of anti- cardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum., 1999, 42(4), 735-741.
53. Shah, N.M.; Khamashta, M.A.; Atsumi, T.; Hughes, G.R. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus, 1998, 7(1), 3-6.
54. Toubi E.; Khamashta M.A.; Panarra A.; Hughes G.R.V. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am. J. Med., 1995, 99(4), 397-401.
55. Rodriguez, A.S.; Oterino, J.A.M.; Hernandez, P.A. Lupus myelitis. Arch. Intern. Med., 1998, 158(20), 2267-2268.
56. Husebye, E.S.; Sthoeger, Z. M.; Dayan, M.; Zinger, H.; Elbirt, D.; Levite, M.; Mozes, E. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann. Rheum. Dis., 2005, 64(8), 1210-1213.
57. Omdal, R.; Brokstad, K.; Waterloo, K.; Koldingsnes, W.; Jonsson, R.; Mellgren, S.I. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur. J. Neurol., 2005, 12(5), 392-398.
58. Arnett, F.C.; Reveille, J.D.; Moutsopoulos, H.M.; Georgescu, L.; Elkon, K.B. Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis Rheum., 1996, 39(11), 1833-1839.
59. Isshi, K.; Hirohata, S. Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum., 1998, 41(10), 1819-1827.
60. Nojima, Y.; Minota, S.; Yamda, A.F.T.; Aotsuka, S.; Yokohari, R. Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus. Ann. Rheum. Dis., 1992, 51(9), 1053-1055.
61. Schneebaum, A.B.; Singleton, J.D.; West, S.G.; Blodgett, J.K.; Allen, L.G.; Cheronis, J.C.; Kotzin, B.L. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am. J. Med., 1991, 90(1), 54-62.
62. The, L.S.; Bedwell, A.E.; Isenberg, D.A.; Gordon, C.; Emery, P.; Charles, P.J.; Harper, M.; Amos, N.; Williams, B.D. Antibodies to protein P in systemic lupus erythematosus. Ann. Rheum. Dis., 1992, (51), 4.
63. Georgescu, L.; Mevorach, D.; Arnett, F.C.; Reveille, J.D.; Elkon, K.B. Anti-P Antibodies and neuropsychiatric lupus erythematosus. Ann. N. Y. Acad. Sci., 1997, 823(Neuropsychiatric manifestations of Systemic Lupus Erythematosis), 263-269.
64. Karassa, F.B.; Afeltra, A.; Ambrozic, A.; Chang, D.M.; De Keyser, F.; Doria, A.; Galeazzi, M.; Hirohata, S.; Hoffman, I.E.A.; Inanc, M.; Massardo, L.; Mathieu, A.; Mok, C.C.; Morozzi, G.; Giovann, S.; Spindler, A.J.; Tzioufas, A.G.; Yoshio, T.; Ioannidis, J.P.A. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: An international meta-analysis. Arthritis Rheum., 2006, 54(1), 312-324.
65. Williams, R.C.; Jr Sugiura, K.; Tan, E.M. Antibodies to microtubule- associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum., 2004, 50(4), 1239-1247.
66. Lefranc, D.; Launay, D.; Dubucquoi, S.; de Seze, J.; Dussart, P.; Vermersch, M.; Hachulla, E.; Hatron, P-Y.; Vermersch, P.; Mouthon, L.; Prin, L. Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach. Arthritis Rheum., 2007, 56(10), 3420-3432.
67. Goetzl, E.J.; Banda, M.J.; Leppert, D. Matrix metalloproteinase in immunity. J. Immunol., 1996, 156(1), 1-4.
68. Trysberg, E.; Blennow, K.; Zachrisson, O.; Tarkowski, A. Intrathecal levels of matrix metalloproteinase in systemic lupus erythematosus with central nervous system engagement. Arthritis Res. Ther., 2004, 6(6), R551-R556.
69. Kwiecinski, J.; Klak, M.; Trysberg, E.; Blennow, K.; Tarkowski, A.; Jin, T. Relationship between elevated cerebrospinal fluid levels of plasminogen activator inhibitor 1 and neuronal destruction in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum., 2009, 60(7), 2094-2101.
70. Brooks, W.M.; Sabet, A.; Sibbitt, W.L Jr.; Barker, P.B.; van Zijl, P.C.; Duyn, J.H.; Moonen, C.T. Neurochemistry of brain lesions determined by spectroscopic imaging in systemic lupus erythematosus. J. Rheumatol., 1997, 24(12), 2323-2329.
71. Sundgren, P.C.; Jennings, J.; Attwood, J.T.; Nan, B.; Gebarski, S.; McCune, W.J.; Pang, Y.; Maly, P. MRI and 2D-CSI MR spectroscopy of the brain in the evaluation of patients with acute onset of neuropsychiatric systemic lupus erythematosus. Neuroradiology, 2005, 47(8), 576-585.
72. Friedman, S.D.; Stidley, C.A.; Brooks, W.M.; Hart, B.L.; Sibbitt, W.L. Jr. Brain injury and neurometabolic abnormalities in systemic lupus erythematosus. Radiology, 1998, 209(1), 79-84.
73. Sibbitt, W.L. Jr.; Haseler, L.J.; Griffey, R.H.; Hart, B.L.; Sibbitt, R.R.; Matwiyoff, N.A. Analysis of cerebral structural changes in systemic lupus erythematosusby proton MR spectroscopy. Am. J. Neuroradiol., 1994, 15(5), 923-928.
74. Jung, R.E.; Segall, J.M.; Grazioplene, R.G.; Qualls, C.; Sibbitt, W.L Jr.; Roldan, C.A. Cortical thickness and subcortical gray matter reductions in neuropsychiatric systemic lupus erythematosus. PLoS One, 2010, 5(3), e9302.
75. Sibbitt, W.L Jr.; Sibbitt, R.R.; Brooks W.M. Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum., 1999, 42(10), 2026-2038.
76. Abreu, M.R.; Jakosky, A.; Folgerini, M.; Brenol, J.C.T.; Xavier, R.M.; Kapczinsky, F. Neuropsychiatric systemic lupus erythematosus: Correlation of brain MR imaging, CT, and SPECT. Clin. Imaging, 2005, 29(3), 215-221.
77. Appenzeller, S.; Carnevalle, A.D.; Li, L.M.; Costallat, L.T.; Cendes, F. Hippocampal atrophy in systemic lupus erythematosus. Ann. Rheum. Dis., 2006, 65(12), 1585-1589.
78. Appenzeller, S.; Faria, A.V.; Li, L.M.; Costallat, L.T.L.; Cendes, F. Quantitative magnetic resonance imaging analyses and clinical significance of hyperintense white matter lesions in systemic lupus erythematosus patients. Ann. Neurol., 2008, 64(6), 635-643.
79. Weiner, S.M.; Otte, A.; Schumacher, M.; Klein, R.; Gutfleisch, J.; Brink, I.; Otto, P.; Nitzsche, E.U.; Moser, E.; Peter, H.H. Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET. Ann. Rheum. Dis., 2000, 59, 377-385.
80. Otte, A.; Weiner, S.M.; Peter, H.H.; Mueller-Brand, J.; Goetze, M.; Moser, E.; Gutfleisch, J.; Hoegerle, S.; Juengling, F.D.; Nitzsche, E.U. Brain glucose utilization in systemic lupus erythematosus with neuropsychiatric symptoms: a controlled positron emission tomography study. Eur. J. Nucl. Med., 1997, 24(7), 787-791.
81. Kao, C-H.; Ho, Y-J.; Lan, J-L.; Changlai, S-P.; Liao, K-K.; Chieng, P-U. Discrepancy between regional cerebral blood flow and glucose metabolism of the brain in systemic lupus erythematosus patients with normal brain magnetic resonance imaging findings. Arthritis Rheum., 1999, 42(1), 61-68.
82. Komatsu, N.; Kodama, K.; Yamanouchi, N.; Okada, S.I.; Noda, S.; Nawata, Y.; Takabayashi, K.; Iwamoto, I.; Saito, Y.; Uchida, Y.; Ito, H.; Yoshikawa, K.; Sato, T. Decreased regional cerebral metabolic rate for glucose in systemic lupus erythematosus patients with psychiatric symptoms. Eur. Neurol., 1999, 42(1), 41-48.
83. Weiner, S.M.; Otte, A.; Schumacher, M.; Brink, I.; Juengling, F.D.; Sobanksi, T.; Nitzsche, E.U.; Peter, H.H. Alterations of cerebral glucose metabolism indicate progress to severe morphological brain lesions in neuropsychiatric systemic lupus erythematosus. Lupus, 2000, 9(5), 386-389.
84. Ainiala, H.; Dastidar, P.; Loukkola, J.; Lehtimaki, T.; Korpela, M.; Peltola, J.; Hietaharju, A. Cerebral MRI abnormalities and their association with neuropsychiatric manifestations in SLE: a population-based study. Scand. J. Rheumatol., 2005, 34(5), 376-382.
85. Axford, J.S.; Howe, F.A.; Heron, C.; Griffiths, J.R. Sensitivity of quantitative 1H magnetic resonance spectroscopy of the brain in detecting early neuronal damage in systemic lupus erythematosus. Ann. Rheum. Dis., 2001, 60, 106-111.
86. Appenzeller, S.; Li, L.M.; Costallat, L.T.; Cendes, F. Evidence of reversible axonal dysfunction in systemic lupus erythematosus: a proton MRS study. Brain, 2005, 128(Pt 12), 2933-2940.
87. Castellino, G.; Govoni, M.; Padovan, M.; Colamussi, P.; Borrelli, M.; Trotta, F. Proton magnetic resonance spectroscopy may predict future brain lesions in SLE patients: a functional multi-imaging approach and follow up. Ann. Rheum. Dis., 2005, 64(7), 1022-1027.
88. Appenzeller, S.; Li, L.M.; Costallat, L.T.L.; Cendes, F. Neuro- metabolic changes in normal white matter may predict appearance of hyperintense lesions in systemic lupus erythematosus. Lupus, 2007, 16(12), 963-971.
89. Tomietto, P.; Annese, V.; D'agostini, S.; Venturini, P.; Torre, G.L.; Vita, S.D.; Ferraccioli, G.F. General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Care Res., 2007, 57(8), 1461-1472.
90. Brooks, W.M.; Sibbitt W.L Jr.; Kornfeld M.; Jung R.E.; Bankhurst A.D.; Roldan C.A. The histopathologic associates of neuro- metabolite abnormalities in fatal neuropsychiatric systemic lupus erythematosus. Arthritis Rheum., 2010, 62(7), 2055-2063.
91. DiFrancesco, M.W.; Holland, S.K.; Ris, M.D.; Adler, C.M.; Nelson, S.; DelBello, M.P.; Altaye, M.; Brunner, H.I. Functional magnetic resonance imaging assessment of cognitive function in childhood-onset systemic lupus erythematosus: a pilot study. Arthritis Rheum., 2007, 56(12), 4151-4163.
92. Navarrete, M.G.; Brey, R.L. Neuropsychiatric systemic lupus erhythematosus. Curr. Treat Opt Neurol., 2000, 2(5), 473-485.
93. O'Neill, S.G.; Schrieber, L. Immunotherapy of systemic lupus erythematosus. Autoimmun. Rev., 2005, 4, 395-401.
94. Denburg, S.D.; Carbotte, R.M.; Denburg, J.A. Cognition and mood in systemic lupus erythematosus. Ann. N. Y. Acad. Sci., 1997, 823, 45-59.
95. Petri, M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus, 1996, 5(Suppl 1), 16-22.
96. Wallace, D. Antimalarial agents and lupus. Rheum. Dis. Clin. North Am., 1994, 20, 243-263.
97. Ntali, S.B.G.; Boumpas, D.T. Cyclophosphamide and Lupus Nephritis: When, how, for how long? Clin. Rev. Allergy Immunol., 2010, [Epub ahead of print].
98. Austin, H.A 3rd.; Klippel, J.H.; Balow, J.E.; le Riche, N.G.; Steinberg, A.D.; Plotz, P.H.; Decker, J.L. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N. Engl. J. Med., 1986, 314(10), 614-619.
99. Barile-Fabris, L.; Ariza-Andraca, R.; Olguín-Ortega, L.; Jara, L.J.; Fraga-Mouret, A.; Miranda-Limón, J.M.; Fuentes de la Mata, J.; Clark, P.; Vargas, F.; Alocer-Varela, J. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann. Rheum. Dis., 2005, 64, 620-625.
100. Houssiau, F.; Vasconcelos, C.; D'Cruz, D.; Sebastiani, G.; Garrido Ed Ede, R.; Danieli, M.; Abramovicz, D.; Blockmans, D.; Mathieu, A.; Direskeneli, H.; Galeazzi, M.; Gül, A, Levy, Y.; Petera, P.; Popovic, R.; Petrovic, R.; Sinico, R.; Cattaneo, R.; Font, J.; Depresseux, G.; Cosyns, J.; Cervera, R. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum., 2002, 46(8), 2121-2131.
101. Ortmann, R.A.; Klippel, J.H. Update on cyclophosphamide for systemic lupus rythematosus. Rheum. Dis. Clin. North Am., 2000, 26(2), 363-375.
102. Strand, V. New therapies for systemic lupus erythematosus. Rheum. Dis. Clin. North Am., 2000, 26(2), 389-407.
103. Allison, A.C. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology, 2000, 47(2-3), 63-83.
104. Ginzler, E.M.; Dooley, M.A.; Aranow, C.; Kim, M.Y.; Buyon, J.; Merrill, J.T.; Petri, M.; Gilkeson, G.S.; Wallace, D.J.; Weisman, M.H.; Appel, G. Mycophenolate mofetil or intravenous cyclo- phosphamide for lupus nephritis. N. Engl. J. Med., 2005, 24(353), 21.
105. Appel, G.; Contreras, G.; Dooley, M.; Ginzler, E.; Isenberg, D.; Jayne, D.; Li, L.; Mysler, E.; Sánchez-Guerrero, J.; Solomons, N.; Wofsy, D. Aspreva lupus management study G. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol., 2009, 20(5), 1103-1112.
106. Isenberg, D.; Appel, G.B.; Contreras, G.; Dooley, M.A.; Ginzler, E.M.; Jayne, D.; Sánchez-Guerrero, J.; Wofsy, D.; Yu, X.; Solomons, N. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford), 2010, 49(1), 128-140.
107. Jacob, A.; Matiello, M.; Weinshenker, B.G.; Wingerchuk, D.M.; Lucchinetti, C.; Shuster, E.; Carter, J.; Keegan, B.M.; Kantarci, O.H.; Pittock, S.J. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch. Neurol., 2009, 66(9), 1128-1133.
108. Vollmer, T.; Stewart, T.; Baxter, N. Mitoxantrone and cytotoxic drugs' mechanisms of action. Neurology, 2010, 74(Suppl 1), S41-6.
109. Zandman-Goddard, G.; Blank, M.; Shoenfeld, Y. Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside. Lupus, 2009, 18, 884-888.
110. Heyneman, C.A.; Gudger, C.A.; Beckwith, J.V. Intravenous immune globulin for inducing remissions in systemic lupus erythematosus. Ann. Pharmacother., 1997, 31, 242-244.
111. Baráth, S.; Soltész, P.; Kiss, E.; Aleksza, M.; Zeher, M.; Szegedi G.; Sipka, S. The severity of systemic lupus erythematosus negatively correlates with the increasing number of CD4+CD25highFoxP3+ regulatory T cells during repeated plasmapheresis treatments of patients. Autoimmunity, 2007, 40(7), 521-528.
112. Murray, E.; Perry, M. Off-label use of rituixmab in systemic lupus erythematosus: a systemic review. Clin. Rheumatol., 2010, [Epub ahead of print].
113. Tokunaga, M.; Saito, K.; Kawabata, D.; Imura, Y.; Fujii, T.; Nakayamada, S.; Tsujimura, S.; Nawata, M.; Iwata, S.; Azuma T.; Mimori, T.; Tanaka, Y. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann. Rheum. Dis., 2007, 66, 470-475.
114. Appenzeller, S.; Cendes, F.; Costallat, L. Acute psychosis in systemic lupus erythematosus. Rheumatol. Int., 2008, 28(3), 237-243.
115. Pego-Reigosa, J.; Isenberg, D. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford), 2008, 47(10), 1498-502.
116. McLaurin, E.Y.; Holliday, S.L.; Williams, P.; Brey, R.L. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology, 2005, 64(2), 297-303.
117. Haupt, M.; Millen, S.; Jänner, M.; Falagan, D.; Fischer-Betz, R.; Schneider, M. Improvement of coping abilities in patients with systemic lupus erythematosus: a prospective study. Ann. Rheum. Dis., 2005, 64, 1618-1623.
118. Navarra, S.; Sang, C.; Hall, S.; Guzman, R.; Gallacher, A.; Levy, R.; Jimenez, R.; Li, E.; Thomas, M.; Kim, H-Y.; Suh, C-H.; Leon, M.; Tanasescu, C.; Lan, J-L.; Yu, C-L.; Pineda, L.; Zhong, Z.; Freimuth, W.; Petri, M. BLISS 52 Study Group. Belimumab, a BlyS-specific inhibitor, reduced disease activity, flares, and steroid use in patients with seropositive systemic lupus erythematosus: BLISS-52 study. Lupus, 2010, (Suppl 19), 12 (Abstract).
119. Furie, R.; Gladman, D.; D'Cruz, D.; Zamani, O.; Wallace, D.; van Vollenhoven, R.; Tegzova, D.; Merrill, J.; Schwarting, A.; Clarke, A.; Doria, A.; Sanchez-Guerrero, J.; Chatham, W.; Manzi, S.; Ginzler, E.; McKay, J.; Stohl, W.; Zhong, Z.; Hough, D.; Cooper, S.; Freimuth, W.; Petri, M. BLISS 76 Study Group. Belimumab, a BLyS-specific inhibitor, reduced disease activity and severe flares in patients with seropositive SLE: BLISS-76 study. Lupus, 2010, (Suppl 19), 13 (Abstract).